Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCI-540 in MDD with Concomitant Anxiety
NCT00621270Phase 2Completed
- Sponsor
- BrainCells Inc.
- Start
- Jan 2008
- Primary completion
- Oct 2009
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of coluracetam in major depressive disorder (MDD) and anxiety disorder (3 arms), sponsored by BrainCells Inc. Primary endpoints: Inventory of Depressive Symptomatology-Clinician Version at 6 weeks and Hamilton Rating Scale for Anxiety at 6 weeks. Started Jan 2008; status: completed.
02
Drugs
coluracetam
03
Conditions
major depressive disorder (MDD)anxiety disorder
Beyond the preview
Go deeper on NCT00621270.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00621270.